Neurobo Pharmaceuticals Stock Five Year Return
| NRBODelisted Stock | USD 2.26 0.06 2.59% |
Neurobo Pharmaceuticals fundamentals help investors to digest information that contributes to Neurobo Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Neurobo Stock. The fundamental analysis module provides a way to measure Neurobo Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neurobo Pharmaceuticals stock.
Neurobo |
Neurobo Pharmaceuticals Company Five Year Return Analysis
Neurobo Pharmaceuticals' Five Year Return is considered one of the best measures to evaluate fund performance, especially from the mid and long term perspective. It shows the total annualized return generated from holding equity for the last five years and represents capital appreciation of the investment, including all dividends, losses, and capital gains distributions.
More About Five Year Return | All Equity Analysis
Five Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Although Five Year Returns can give a sense of overall investment potential, it is recommended to compare equity performance with similar assets for the same five year time interval. Similarly, comparing overall investment performance over the last five years with the appropriate market index is a great way to determine how this equity instrument will perform during unforeseen market fluctuations.
| Competition |
According to the company disclosure, Neurobo Pharmaceuticals has a Five Year Return of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Neurobo Five Year Return Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neurobo Pharmaceuticals' direct or indirect competition against its Five Year Return to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neurobo Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Neurobo Pharmaceuticals by comparing valuation metrics of similar companies.Neurobo Pharmaceuticals is currently under evaluation in five year return category among its peers.
Neurobo Fundamentals
| Return On Equity | -1.61 | |||
| Return On Asset | -0.74 | |||
| Current Valuation | (1.18 M) | |||
| Shares Outstanding | 8.62 M | |||
| Shares Owned By Insiders | 65.23 % | |||
| Shares Owned By Institutions | 12.71 % | |||
| Number Of Shares Shorted | 34.27 K | |||
| Price To Earning | (1.44) X | |||
| Price To Book | 1.57 X | |||
| Revenue | 7 K | |||
| EBITDA | (15.88 M) | |||
| Net Income | (12.47 M) | |||
| Cash And Equivalents | 8.85 M | |||
| Cash Per Share | 9.96 X | |||
| Total Debt | 203 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 8.07 X | |||
| Book Value Per Share | 1.50 X | |||
| Cash Flow From Operations | (10.8 M) | |||
| Short Ratio | 0.87 X | |||
| Earnings Per Share | (4.29) X | |||
| Target Price | 26.67 | |||
| Beta | -0.28 | |||
| Market Capitalization | 20.33 M | |||
| Total Asset | 22.78 M | |||
| Retained Earnings | (108.27 M) | |||
| Working Capital | 16.55 M | |||
| Current Asset | 21.62 M | |||
| Current Liabilities | 11.75 M | |||
| Net Asset | 22.78 M |
About Neurobo Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neurobo Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurobo Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurobo Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Neurobo Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neurobo Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurobo Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Neurobo Stock
| 0.81 | PPERY | Bank Mandiri Persero | PairCorr |
| 0.8 | PPERF | Bank Mandiri Persero | PairCorr |
| 0.75 | BKRKF | PT Bank Rakyat | PairCorr |
| 0.81 | BKRKY | Bank Rakyat | PairCorr |
Moving against Neurobo Stock
| 0.82 | CSCO | Cisco Systems | PairCorr |
| 0.78 | AXP | American Express Fiscal Year End 24th of January 2025 | PairCorr |
| 0.78 | HD | Home Depot | PairCorr |
| 0.74 | BAC | Bank of America Fiscal Year End 10th of January 2025 | PairCorr |
| 0.71 | DIS | Walt Disney | PairCorr |
The ability to find closely correlated positions to Neurobo Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neurobo Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neurobo Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neurobo Pharmaceuticals to buy it.
The correlation of Neurobo Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurobo Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurobo Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neurobo Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurobo Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Other Consideration for investing in Neurobo Stock
If you are still planning to invest in Neurobo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neurobo Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |